medigraphic.com
Colegio de Medicina Interna de México.

2022, Number 2

<< Back Next >>

Med Int Mex 2022; 38 (2)

Oral anticoagulants: A challenge in therapeutic adherence

Martínez-Sánchez LM, Urrego-Vásquez A, Gaviria-García JR, Ospina-SánchezJP, Jaramillo-Jaramillo LI, Hernández-Restrepo F

Language: Spanish
References: 52
Page: 355-365
PDF size: 400.22 Kb.


ABSTRACT

Oral anticoagulants have been a great ally for physicians in thromboembolic events because they represent a great challenge in their management, causing a high number of deaths in developed countries. Several drugs have been created, such as vitamin K antagonists, that require strict monitoring, over time, molecules known as the direct oral anticoagulants have been developed, these have allowed their administration to be safer and not have to carry out such strict controls. This paper reviews bibliography on the characteristics and therapeutic adherence of direct oral anticoagulants and how they impact thrombotic events. Literature review was carried out, searching for original articles and systematic reviews in PubMed and ScienceDirect. We selected 80 articles, included 52 that fulfilled the stated objective, from these the description of the present text was developed in which aspects related to the epidemiology, pharmacology and adherence of direct oral anticoagulants are developed. Direct oral anticoagulants are drugs that are increasingly prescribed by specialists because they provide greater patient safety but require adequate adherence by these patients to achieve the expected therapeutic effect.


REFERENCES

  1. Izazola C, Majluf A, Mandoki J, Molina J. Educación y evaluación del conocimiento del paciente en tratamiento con anticoagulantes orales. Rev Med Hosp Gen Mex 2014; 77 (1): 24-32.

  2. Jaramillo RG, Jiménez JD, Pinilla AE. Uso de anticoagulantes orales directos en la práctica clínica. Rev Fac Med 2016; 64: 295-308.

  3. Galván Y, Carrillo R. Reversión de la anticoagulación en cirugía de urgencia. Rev Mex Anest 2014; 37: S407-S413.

  4. Bergmann JF, Cohen AT, Tapson VF, Godhaber SZ, Kakkar AK, Deslandes B, et al. Venous tromboembolism risk and prophylaxis in hospitalised medically ill patients. Thromb Haemost 2015; 103: 736-48. doi: 10.1160/TH09-09-0667.

  5. Garcia LF. Análisis de la anticoagulación perioperatoria incluyendo a los nuevos anticoagulantes orales. Med Int Mex 2016; 32 (4): 426-435.

  6. Laverde LP, Gómez SE, Montenegro AC, Lineros A, Wills B, Buitrago AF. Experiencia de una clínica de anticoagulación. Rev Colomb Cardiol 2015; 22: 224-230. doi: 10.1016/j. rccar.2015.04.008.

  7. Machado-Alba JE, García-Betancur S, Villegas-Cardona F, Medina-Morales DA. Patrones de prescripción de los nuevos anticoagulantes orales y sus costos económicos en Colombia. Rev Colomb Cardiol 2016; 23: 277-285. DOI: 10.1016/j.rccar.2015.08.005.

  8. Valdés Y, Pantaleón O, Quiñones M. Adherencia al tratamiento anticoagulante oral por enfermedad tromboembólica venosa en adultos mayores. Rev Cubana Angiol Cir Vasc 2017; 18 (1): 19-34.

  9. Buitargo F. Adherencia terapéutica. ¡Qué difícil es cumplir! Aten Primaria. 2011; 43 (7): 343-4. DOI: 10.1016/j. aprim.2011.05.002

  10. Ortiz G, Ariza F, Trujillo A, Bejarano A, et al. Manejo del sangrado y la coagulación en la práctica clínica. Evaluación de la evidencia y recomendaciones mediante estrategia GRADE. Primera reunión de expertos. Acta Colomb Cuid Intensivo 2016; 16 (3): 172-194. DOI: 10.1016/j.acci.2016.04.001.

  11. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011; 365: 2002-12. DOI: 10.1056/ NEJMsa1103053.

  12. Schulman S, Beyth R, Kearon C, Levine M. Hemorrhagic complications of anticoagulant and thrombolytic treatment. American College of Chest Physicians Evidence- Based Clinical Practice Guidelines AND (8th edition) AND Chest 2008; 133: 257-298. doi: 10.1378/chest.08-0674.

  13. lania EM, Vázquez E, García F, Fajardo A, Caravaca P, Adamuz C. Tiempo en rango terapéutico de los pacientes que siguen tratamiento con derivados cumarínicos en la práctica clínica diaria. Cardiocore 2013; 48 (4): 158-61. DOI: 10.1016/j.carcor.2012.10.004.

  14. Selby R, Borah B, McDonald H, Henk H, Crowther M, Wells P. Impact of thromboprophylaxis guidelines on clinical outcomes following total hip and total knee replacement. Thrombosis Research 2012; 130 (2): 166-172. doi: 10.1016/j.thromres.2012.01.013.

  15. Bautista M, Llinás A, Bonilla G, Mieth K, Diaz M, Rodriguez F. Thromboprophylaxis after major orthopedic surgery: improving compliance with clinical practice guidelines. Thromb Res 2016; 137: 113-118. https://doi.org/10.1016/j. thromres.2015.10.020.

  16. Peidro-Garcés L, Otero-Fernandez R, Lozano-Lizarraga L. Adherence to and satisfaction with oral outpatient thromboembolism prophylaxis compared to parenteral: SALTO study. Rev Esp Cir Ortop Traumatol 2013; 57: 53-60. doi: 10.1016/j.recot.2012.10.009.

  17. Moreto A, Sierra C, Iruin G, Martin X, Garcia JC. Disorders of primary hemostasis: purpurae and plaquetary alterations. Medicine 2016; 12 (22): 1267-1274.

  18. Boned-Ombuena A, Pérez-Panadés J, López-Maside A, Miralles-Espí M, GuardiolaVilarroig S, Adam Ruiz D, et al. Prevalence of oral anticoagulation and quality of its management in primary healthcare: A study by the Health Sentinel Network of the Region of Valencia (Spain). Aten Primaria 2017. pii: S0212-6567 (16) 30314-6. doi: 10.1016/j.aprim.2016.11.015.

  19. Anguita M, Bertomeu V, Cequier A. Calidad de la anticoagulación con los antagonistas de la vitamin K en España: prevalencia de mal control y factores asociados. Rev Esp Cardiol 2015; 68 (9): 761-768. DOI: 10.1016/j. recesp.2014.11.022.

  20. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857- 867. doi: 10.7326/0003-4819-146-12-200706190-00007.

  21. Nakamura A, Ago T, Kamouchi M, Hata J, et al., on behalf of the Fukuoka Stroke Registry Investigators. Intensity of anticoagulation and clinical outcomes in acute cardi- oembolic stroke: the Fukuoka Stroke Registry. Stroke 2013; 44: 3239-3242. doi: 10.1161/STROKEAHA.113.002523.

  22. Yamashiro K, Kurita N, Tanaka R, Ueno Y, Miyamoto N, Hira K, et al. Adequate adherence to direct oral anticoagulant is associated with reduced ischemic stroke severity in patients with atrial fibrillation. J Stroke Cerebrovasc Dis 2019; 28 (6): 1773-1780. doi:10.1016/j.jstrokecerebrovasdis. 2018.09.019.

  23. Fernández J, Brugada J. Farmacología del dabigatrán y su manejo clínico. Rev Esp Cardiol Supl 2012; 12B: 18-24. DOI: 10.1016/S1131-3587(12)70047-X

  24. Gomez A, Terleira AI, Suarez ML, Vargas E. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thromb Res 2014; 134: 774-82. oi: 10.1016/j.thromres.2014.06.020.

  25. Pautas E, Monti A, Breining A. Farmacología clínica comparada de los anticoagulantes orales: antivitamina K y anticoagulantes orales directos. EMC- Tratado de Medicina 2016; 20 (3): 1-5. https://doi.org/10.1016/S1636- 5410(16)79460-8.

  26. Oprea AD, Noto CJ, Halaszynski TM. Risk stratification, perioperative and periprocedural management of the patient receiving anticoagulant therapy. J Clin Anesth 2016; 34: 586-599. doi: 10.1016/j.jclinane.2016.06.016.

  27. Arcelus JI, Cairols M, Granero X, Jiménez D, Monreal M, Vicente V. Nuevos anticoagulantes orales: una visión multidisciplinaria. Med Clin (Barc) 2009; 133 (13): 508-12. DOI: 10.1016/j.medcli.2009.03.027

  28. Capodanno D, Capranzano P, Giacchi G, Calvi V, Tamburino C. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients. Int J Cardiol 2013; 167 (4): 1237-41. doi: 10.1016/j. ijcard.2012.03.148.

  29. O’Dell KM, Igawa D, Hsin J. New oral anticoagulants for atrial fibrillation: a review of clinical trials. Clin Ther 2012; 34: 894-901. doi: 10.1016/j.ijcard.2012.03.148.

  30. Djulbegovic M, Lee AI. An update on the "novel" and direct oral anticoagulants, and long-term anticoagulant therapy. Clin Chest Med 2018; 39 (3): 583-593. doi: 10.1016/j. ccm.2018.04.010.

  31. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al; American College of Cardiology/American Heart AssociationTask Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64 (21): e1-76. https://doi.org/10.1161/ CIR.0000000000000041.

  32. Vaanholt MCW, Weernink MGM, von Birgelen C, Groothuis- Oudshoorn CGM, IJzerman MJ, van Til JA. Perceived advantages and disadvantages of oral anticoagulants, and the trade-offs patients make in choosing anticoagulant therapy and adheringto their drug regimen. Patient Educ Couns 2018; 101 (11): 1982-1989. doi: 10.1016/j. pec.2018.06.019.

  33. Al-Khalili F, Lindström C, Benson L. Adherence to anticoagulant treatment with apixaban and rivaroxaban in a real-world setting. CTRS in Cardiology 2016; 18 (2016): 1-4. https://doi.org/10.1016/j.ctrsc.2016.03.003

  34. Bellamy L, Rosencher N, Eriksson BI. Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate. Dovepress 2009; 3: 173-7. doi: 10.2147/ppa.s3682

  35. Sanfélix-Gimeno G, Rodriguez-Bernal CL, Hurtado I, Baixauli-Perez C, Librero J, Peiró S. Adherence to oral anticoagulants in patients with atrial fibrillation—a population-based retrospective cohort study linking health information systems in the Valencia region, Spain: a study protocol. BMJ Open 2015; 5: e007613. doi: 10.1136/ bmjopen-2015-007613.

  36. Diaz ML. La adherencia terapéutica en el tratamiento y la rehabilitación: implicaciones para el profesional de la conducta y la salud. Griot 2014; 7 (1): 73-84.

  37. Arcelus JI, Felecissimo P, for the DEIMOS Investigators. Venous thromboem- boprophylaxis duration and adherence to international guidelines in patients undergoing major orthopedic surgery: results of an international, longitudinal, observational DEIMOS registry. Thromb Res 2013; 131: e240-e246. doi: 10.1016/j.thromres.2013.03.014.

  38. Abdou JK, Auyeung V, Patel JP, Arya R. Adherence to longterm anticoagulation treatment, what is known and what the future might hold. Br J Haematol 2016; 174 (1): 30-42. doi: 10.1111/bjh.14134.

  39. Kääriäinen M, Paukama M, Kyngäs H. Adherence with health regimens of patients on warfarin therapy. J Clin Nurs 2013; 22 (1-2): 89-96. doi: 10.1111/j.1365- 2702.2012.04079.x.

  40. Di Minno A, Spadarella G, Tufano A, Prisco D, Di Minno G. Ensuring medication adherence with direct oral anticoagulant drugs: lessons from adherence with vitamin K antagonists (VKAs). Thromb Res 2014; 133 (5): 699-704. doi: 10.1016/j.thromres.2014.01.016.

  41. Al-Omair S, Ahmed N, Yazid N, Abdulwahab N, Bayoumy NMK. Compliance with and awareness about long‐term oral anticoagulant therapy among Saudi patients in a University Hospital, Riyadh, Saudi Arabia. J Appl Hematol 2016; 7: 10-6. DOI: 10.4103/1658-5127.181107

  42. Davis NJ, Billett HH, Cohen HW, Arnsten JH. Impact of adherence, knowledge, and quality of life on anticoagulation control. Ann Pharmacother 2005; 39 (4): 632-6.

  43. Suzuki T, Shiga T, Omori H, Tatsumi F, Nishimura K, Hagiwara N. Adherence to medication and characteristics of Japanese patients with non valvular atrial fibrillation. J Cardiol 2017; 70 (3): 238-243. doi: 10.1016/j.jjcc.2016.11.009.

  44. Precioso-Costa FJ, Larré-Muñoz MJ, Navarro-Ros FM, Silvero YA, Garrido-Sepúlveda L, Llisterri Caro JL. Level of control and treatment adherence of anticoagulation with acenocoumarol in primary care. Semergen 2016; 42 (6): 363-9. doi: 10.1016/j.semerg.2015.08.004.

  45. Brown JD, Shewale AR, Talbert JC. Adherence to rivaroxaban, dabigatran, andapixaban for stroke prevention in incident, treatment-naïve nonvalvular atrial fibrillation. J Manag Care Spec Pharm 2016; 22 (11): 1319-1329. doi: 10.18553/jmcp.2016.22.11.1319.

  46. Bartoli-Abdou JK, Patel JP, Crawshaw J, Vadher B, Brown A, Roberts LN, et al. Exploration of adherence and patient experiences with DOACs one year after switching from vitamin-K antagonists-insights from the switching study. Thromb Res 2018; 162: 62-68. doi: 10.1016/j. thromres.2017.12.021.

  47. Barrios V, Escobar C, Barón G, Gómez JJ, Recalde E, et al. Quality of life, adherence and satisfaction of patients with auricular fibrillation treated with dabigatran or vitamin K antagonists. Rev Clín Esp 2019; 219 (6): 285-292. doi: 10.1016/j.rce.2018.12.006.

  48. Castellucci LA, Shaw J, van der Salm K, Erkens P, Le Gal G, Petrcich W, et al. Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale. Thromb Res 2015; 136 (4): 727-31. doi:10.1016/j.thromres.2015.07.007.

  49. Grymonpre RE, Didur CD, Montgomery PR, Sitar DS. Pill count, self-report, and pharmacy claims data to measure medication adherence in the elderly. Ann Pharmacother 1998; 32: 749-54. doi: 10.1345/aph.17423.

  50. Yim-Lam W, Fresco P. Medication adherence measures: An overview. Biomed Res Int 2015; 2015: 217047. doi: 10.1155/2015/217047.

  51. Rodriguez RA, Carrier M, Wells PS. Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation? J Thromb Haemost 2013; 11 (2): 390-4. https://doi.org/10.1111/jth.12086

  52. Hohmann C, Eickhoff C, Kaemmerer W, Schulz M. Compliance with antithrombotic guidelines in surgery patients in German hospitals: A multicenter study involving pharmacy interns. Clin Appl Thrombosis/Hemostasis 2012; 18 (3): 299-304. doi: 10.1177/1076029611412368.




2020     |     www.medigraphic.com